ARTICLE | Politics, Policy & Law
Zarxio lessons
What Sandoz's Mark McCamish thinks are the take-homes from the Zarxio adcomm
January 26, 2015 8:00 AM UTC
Sandoz is blazing a trail for commercialization of biosimilars in the U.S. with its application to market Zarxio, a biosimilar version of Amgen Inc.'s Neupogen filgrastim. The Novartis AG unit is using its first-mover position to force FDA and the courts to make decisions that will shape the economic and regulatory landscape for biosimilars.
BioCentury recently spoke with Mark McCamish, global head of biopharmaceuticals and oncology injectables development at Sandoz...